In 2025, Jiahui International Hospital's international outpatient volume exceeded 100,000 visits — ranking first among Shanghai's international hospitals; overseas inquiries in 2026 have grown several-fold year-on-year. This growth is not isolated.
Xiang Naiqiang, a member of Jiahui's executive committee, disclosed at the WTO 2026 Geneva Public Forum that in 2025 China's key international-facing hospitals received 1.28 million international patient visits (+73.6% YoY), of which 413,000 came specifically for treatment (+63% YoY). The behavioral pattern has shifted from 'incidental care during a trip' to 'purpose-built medical travel'.
Drivers include: approval and accessibility of frontier therapies such as solid-tumor CAR-T, the twelve-language service capacity of Shanghai's international hospital system, significant cost advantages over the West, and visa-free entry plus medical visa facilitation. MedBridge Shanghai provides end-to-end service from consultation and medical record pre-screening to on-ground accompaniment.
How MedBridge Shanghai Helps
As a leading cross-border medical platform in Shanghai, MedBridge Shanghai provides end-to-end support: free medical record review and specialist appointments, pre-travel coordination and visa support, airport pickup and accommodation, full medical interpretation and coordination, and post-treatment follow-up with remote consultations.
For more information on CAR-T treatment options and costs, contact our medical advisors, or explore our medical services and partner hospitals.
[Disclaimer] This article is not medical advice. Indications, costs and availability of cell therapy must be confirmed by in-person physician evaluation and the hospital's official plan.